

# **Combination Venetoclax and Selinexor Effective in Relapsed Refractory Multiple Myeloma with Translocation t(11;14)**

## **Supplementary Appendix**


### **Table of Contents:**

**Supplementary Figure and Text (page 2-3)**

**Supplementary Table (page 4)**

Nina Nguyen, MD<sup>1#</sup>, Sana Chaudhry, BSc<sup>1#</sup>, Tulasigeri M. Totiger, PhD<sup>1#</sup>, Robert Diaz, MS<sup>1</sup>, Evan Roberts, BSc<sup>1</sup>, Skye Montoya, BSc<sup>1</sup>, Gabriel Pardo BSc<sup>1</sup>, Alejandro Pardo BSc<sup>1</sup>, Jumana Afaghani, BSc<sup>1</sup>, Maurizio Affer, MSc<sup>1</sup>, Jacob Jahn, BSc<sup>1</sup>, Terrence Bradley, MD<sup>3</sup>, Francesco Maura, MD<sup>2</sup>, Dickran Kazandjian, MD<sup>2</sup>, Daniel Bilbao, PhD<sup>1</sup>, Jennifer Chapman, MD<sup>4</sup>, Ola Landgren, MD, PhD<sup>2</sup>, James Hoffman, MD<sup>2\*</sup>, and Justin Taylor, MD<sup>3\*</sup>

# Supplementary Figure 1



**Supplementary Figure 1. The combination of selinexor and venetoclax show higher levels of synergy and decreased levels of Cyclin D1, XPO1, and MCL-1 protein levels in KMS12BM.**

OPM2 and KMS12BM were treated with increasing doses of selinexor and venetoclax for 72 hours and cell viability was measured using CellTiter-Glo. Contour plots were calculated using the Bliss Independence model and were generated using the SynergyFinder web application. Red indicates synergism and green indicates antagonism (**Panel A and B**). The synergy of OPM2 and KMS12BM was compared using Combination Index (CI) values. The difference was measured using Student's t-test (**Panel C**). The synergy was also calculated using the CompuSyn software.

Combination Index values  $>1$  indicates antagonism,  $=1$  indicates additivity,  $<1$  indicates synergy (**Panel D and E**). OPM2 and KMS12BM were treated with selinexor (200nM) and venetoclax(1 $\mu$ M) for 16 hours and subjected to a Western blot using various antibodies as indicated (**Panel F**). The normalized protein levels of p65, p53, Cyclin D1, XPO1, and MCL-1 was calculated by the intensity of the Western blot bands using Image J software (**Panel G and H**).

<b>Cell Lines</b>	<b>MM IgH translocation</b>
U266-B1	t(11;14)(CCND1/IGH)
KMS-12-BM	t(11;14)(CCND1/IGH)
MOLP-8	t(11;14)(CCND1/IGH)
SK-MM-2	t(11;14)(CCND1/IGH)
NCI-H929	t(4;14)(MMSET/IGH)
LP-1	t(4;14)(MMSET/IGH)
OPM-2	t(4;14)(MMSET/IGH) t(?;20)(?;MAFB)
EJM	t(14;20)(IGH/MAF)
L-363	t(6;20)(?;MAFB)
KARPAS-620	t(8;11)(CCND1)
JJN-3	t(14;16)(IGH/MAF)
MM1S	t(14;16)(IGH/MAF)
KMS-11	t(4;14)(MMSET/IGH) t(14;16)(IGH/MAF)
RPMI-8226	t(16;22)(MAF;IGL)
AMO-1	-
MC-CAR	-
IM-9	-
ARH-77	-

**Supplemental Table 1. List of multiple myeloma (MM) cell lines according to their immunoglobulin heavy chain (IgH) translocation.**

Abbreviations: CCND1, Cyclin D1; IGH, immunoglobulin heavy chain; MMSET, multiple myeloma SET domain; IGL, immunoglobulin light chain